SF1126, under development by Semafore Pharmaceuticals, is an inhibitor of the PI3K pathway. This pathway is clearly relevant to GIST. For information at the manufacturer's site click here.
According to the Semafore news release, SF1126 is available in a Phase I trial being conducted at these locations:
- Virginia Piper Cancer Center, Scottsdale
contact patient care coordinator, Joyce Ingold RN MSN OCN
TGen Clinical Research Services
Patient Care Coordinator
10460 N. 92nd Street, Suite 206
Scottsdale, AZ 85258
- Indiana University Cancer Center
The trial name is "A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors." It is not yet listed on the clinicaltrials.gov website.
For more information please contact TGen Clinical Research Services.